Session » Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II

Date: Monday, November 14, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1880

A Large Proportion of Patients in an Early Systemic Sclerosis-Associated Interstitial Lung Disease Cohort Have Coexisting Pulmonary Hypertension

9:00AM-11:00AM: Abstract Number: 1867

An Abnormal Nailfold Capillaroscopy Pattern Is Common in Patients with Connective Tissue Disease and Is Associated with Pulmonary and Oesophageal Involvement, Even in the Absence of Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1900

Anti-Topoisomerase Positive Systemic Sclerosis – Prognosis Infaust?

9:00AM-11:00AM: Abstract Number: 1885

Can Nailfold Videocapillaroscopy Images be Interpreted Reliably By Different Observers? Results of an Inter-Reader and Intra-Reader Exercise Among Rheumatologists with Different Experience in This Field

9:00AM-11:00AM: Abstract Number: 1877

Confirmatory Factor Analysis and Assessment of Differential Item Functioning of the Satisfaction with Appearance Scale in Systemic Sclerosis: A Comparison Across Sex, Race/Ethnicity and Disease Subtype

9:00AM-11:00AM: Abstract Number: 1902

Detecting the Pulmonary Vascular Involvement and the Changes in Gene Activation Profiles at Early Stage of Systemic Sclerosis in Patients with Raynaud Phenomenon

9:00AM-11:00AM: Abstract Number: 1903

Determining Disease Course in Localized Scleroderma: A Prospective Cohort Study

9:00AM-11:00AM: Abstract Number: 1896

Efficacy of Pulmonary Arterial Hypertension-Specific Drugs Combination Therapy in Survival of Patients with Pulmonary Arterial Hypertension Associated with Systemic Sclerosis and Other Connective Tissue Diseases

9:00AM-11:00AM: Abstract Number: 1884

Esophageal Dilation and Interstitial Lung Disease Incidence and Progression in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1891

Excellent Reliability of Semiquantitative Nailfold Capillaroscopy Assessment in a Systemic Sclerosis Cohort – a Pilot Study

9:00AM-11:00AM: Abstract Number: 1883

Exercise Habits and Factors Associated with Exercise in Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network (SPIN) Cohort Study

9:00AM-11:00AM: Abstract Number: 1870

First Pilot Study of an Implantable Loop Recorder (ILR) in Systemic Sclerosis Detects Significant Cardiac Arrhythmias with CMR Abnormalities

9:00AM-11:00AM: Abstract Number: 1890

Functional Disability and Its Predictors in Systemic Sclerosis: A Study from the Desscipher Project within the European Scleroderma Trials and Research Group

9:00AM-11:00AM: Abstract Number: 1892

Immunosignature Technology Differentiates Patients with Systemic Sclerosis and Internal Organ Involvement

9:00AM-11:00AM: Abstract Number: 1895

Increased CXCL4/PF4 Presence in Systemic Sclerosis and Absence of Heparin Directed Autoantibodies

9:00AM-11:00AM: Abstract Number: 1894

Increased Mortality in Systemic Sclerosis Patients with Fibrosing Myopathy

9:00AM-11:00AM: Abstract Number: 1873

Longitudinal Analysis of Modified Rodnan Skin Score in Systemic Sclerosis Using Group-Based Trajectory Modelling

9:00AM-11:00AM: Abstract Number: 1874

Low Rate of Progression in Cases of Isolated Raynaud’s Phenomenon Screened By Nailfold Videocapillaroscopy and Antinuclear Antibody Status Supports Negative Predictive Value of These Tests

9:00AM-11:00AM: Abstract Number: 1869

Mental Health Care in Systemic Sclerosis; Rates of Utilization and Associated Factors in the Scleroderma Patient-Centered Intervention Network Cohort

9:00AM-11:00AM: Abstract Number: 1887

Olfactory Impairment Is Associate with Cognitive Dysfunction and Regional Brain Atrophy in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1875

Physical Activity in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1871

Predicting Vascular Complications in Systemic Sclerosis: A Prospective Cohort Study

9:00AM-11:00AM: Abstract Number: 1889

Predictors of Acro-Osteolysis in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1882

Predictors of Response to Methotrexate in Patients with Eosinophilic Fasciitis (Shulman’s Disease)

9:00AM-11:00AM: Abstract Number: 1876

Prevalence of Anti-RNA Polymerase III IgG Antibody in a Cohort of Patients with Delayed Wound Healing

9:00AM-11:00AM: Abstract Number: 1893

Prevalence of Antiphospholipid Antibodies in Systemic Sclerosis: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 1868

Rates and Predictors of Physical Therapy and Occupational Therapy Utilization in Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study

9:00AM-11:00AM: Abstract Number: 1888

Reliability, Validity, and Sensitivity to Change of the Simplified Duruoz Hand Index in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1886

Right Ventricular Load-Adaptability and Response to Therapy in Scleroderma Versus Idiopathic Pulmonary Arterial Hypertension

9:00AM-11:00AM: Abstract Number: 1901

Screening for Pulmonary Arterial Hypertension in an Unselected Prospective Systemic Sclerosis Cohort

9:00AM-11:00AM: Abstract Number: 1878

Speckle Tracking Echocardiography: A Sensitive Technique for Detecting Early Left Ventricular Dysfunction in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1881

Targeting Oncostatin M in the Target Tissue: Assessment of in-Vivo Affinity and Target Engagement of an Anti-OSM Monoclonal Antibody By Combining Blood and Skin Blister Fluid Data

9:00AM-11:00AM: Abstract Number: 1879

The Correlation Between Oxidized Low-Density Lipoprotein and Clinical Manifestations in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1872

The Effect of Cyclophosphamide on Pulmonary Function and Dependence on Disease Activity of Interstitial Lung Disease Associated with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1899

The Intestinal Involvement in Systemic Sclerosis Is Characterized By a Peculiar Gut Microbiota

9:00AM-11:00AM: Abstract Number: 1898

The Lack of Association of Osteoporosis with Proton Pump Inhibitor in Scleroderma: A UK Single Centre Cohort Experience

9:00AM-11:00AM: Abstract Number: 1897

Vitamin-D Levels and Gastrointestinal (GI) Manifestations in Systemic Sclerosis (SSc)

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].